SanBio Company Limited
FY2027 1st quarter 2Q Interim Financial Results Summary (Japanese GAAP) (Consolidated)
Operating loss primarily due to commercialization costs for SB623 and manufacturing and sales approval-related expenses for Akugo; however, ordinary income improved due to foreign exchange gains. The full-year FY2027 outlook is as disclosed, and dividend guidance is undecided. Financial position shows net assets decreased; cash and deposits declined. Going forward, push for proper use of Akugo and accelerate global expansion including the United States.
Key Figures
- FY2027 interim period Operating loss △1,909 million yen
- FY2027 interim period Ordinary loss △1,730 million yen
- Net loss attributable to owners of parent △1,791 million yen
- Cash and cash equivalents 12,677 million yen
- Total assets 13,645 million yen
AI要約
Overview of performance
During this interim period, operating loss arose mainly from SB623 clinical and manufacturing/sales approval related expenses, while ordinary income declined due to recording foreign exchange gains. Net loss attributable to owners of parent improved year over year. Ongoing efforts to promote appropriate use and to stabilize supply after market launch are expected to contribute to sustainable growth opportunities.
Financial position and cash flows
Current assets decreased, and cash and deposits declined significantly. Net assets decreased due to lower foreign exchange translation adjustments and recorded interim losses. Cash flows show outflow from operating activities, inflows from investing activities such as redemption of time deposits, and outflows from financing activities including repayment of long-term borrowings.
SanBio Company Limited
Company overview · Stock price · Financial data · All IR
